The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).
 
David Bing Zhen
Consulting or Advisory Role - Cornerstone Pharmaceuticals; Ipsen; Jazz Pharmaceuticals
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Cornerstone Pharmaceuticals (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Legend Biotech (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); TME Pharma (Inst)
 
Anna Moseley
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Regeneron; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Earle F Burgess
Stock and Other Ownership Interests - Becton Dickinson; Exelixis; Gilead Sciences; Macrogenics
Honoraria - Exelixis
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Astellas Pharma; Pfizer
 
Elizabeth M. Swisher
Leadership - IDEAYA Biosciences
Other Relationship - Novartis
 
Carl Michael Gay
Honoraria - American Society for Radiation Oncology; Aptitude Health; Daiichi Sankyo Nordics; DAVA Pharmaceuticals; Peerview; Targeted Oncology
Consulting or Advisory Role - Abdera Therapeutics; AstraZeneca; Catalyst Pharmaceuticals; G1 Therapeutics; Jazz Pharmaceuticals; Monte Rosa Therapeutics; Pharmerit
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - US-20240011103-A1 MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSES
Travel, Accommodations, Expenses - American Society for Radiation Oncology; Dava Oncology; ESMO; IASLC; MJH Live Events; Roche/Genentech
 
Lauren Averett Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Lilly; Flame Biosciences; Genentech/Roche; GlaxoSmithKline; Guardant Health; Janssen; Merck; Merus; MSD Oncology; Novartis; OncoCyte; Pfizer; Regeneron; Sanofi
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Merck; Merus; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst)
 
Haider Mahdi
No Relationships to Disclose
 
Jason S. Starr
Consulting or Advisory Role - Cancer Expert Now; Helsinn Therapeutics; Ipsen; Natera; Pfizer; Taiho Oncology; Tempus; Tersera
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Camurus (Inst); Incyte (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Camurus
 
Megan Othus
Consulting or Advisory Role - Biosight; Cascadia Labs; Daiichi Sankyo; Glycomimetics; Merck
Other Relationship - Celgene; Glycomimetics; Grifols
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Foundation Medicine; Guardant Health; Immuneoncia; Lilly; Lunit; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; BMS; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EOM Pharmaceuticals; Gaido; Iylon; LabCorp; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Prosperdtx; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation